miDiagnostics announced the completion of a €30 million Series D funding round led by Thermo Fisher Scientific. This funding will accelerate the development of a groundbreaking sterility test for batch release and related quality control tests for the BioPharma Industry, utilizing miDiagnostics’ proprietary qPCR technology.
The Series D funding round is further enhanced by the continued support of current investors Alychlo, VMF Invest, and Pamica, who share a vision for the future of healthcare technology.
KEY QUOTES:
“Our continued investment in miDiagnostics reflects our confidence in their vision and the transformative potential of their technology. We believe that with the support of Thermo Fisher Scientific, miDiagnostics is well-capitalized to make significant strides in improving healthcare outcomes.”
- Urbain Vandeurzen, corner stone Investor and Chairman of miDiagnostics
“We are thrilled to have the support of Thermo Fisher Scientific as we advance our mission to revolutionize sterility testing in the biopharma sector. This funding will enable us to expedite our development efforts and leverage Thermo Fisher’s expertise for the commercialization of our pioneering products.”
- Katleen Verleysen, CEO of miDiagnostics
“Our investment in miDiagnostics underscores its innovative approach to sterility testing and the potential it could have on enhancing patient safety and outcomes for the biopharma industry. This is well aligned with our Mission to enable our customers to make the world healthier, cleaner and safer.”
- Bhooshi De Silva, head of strategic capital, Thermo Fisher Scientific
